Biologics & Injectables Index
Convert Unblinded Payer Perceptions into Insights
- Examine Payer Reactions to Healthcare Trends: Analyze how payers respond to key healthcare topics and market developments each quarter to stay ahead of industry shifts.
- Assess Payer Management Strategies: Evaluate payer management techniques, site-of-care trends, and administrative burden via Access Management Topics.
- Review Therapeutic Area Trends and Emerging Therapies: Gain deep insights into specific therapeutic areas, including disruptive market events and payer perceptions of new and emerging therapies.
- Inform Strategy and Market Access Decisions: Access insights from leading payer stakeholders representing 75% of Commercial and Medicare lives.
Track Biologics and Injectables Trends with Confidence
What Our Clients Are Saying
How We Can Help
Harness the power of MMIT’s Biologics & Injectables Index, built on robust field research with an industry-leading panel of pharmacy decision-makers. 100% of panellists are either active P&T participants or control access for pharmaceuticals for their organizations, delivering unparalleled market access visibility and actionable payer perspectives to inform your team’s strategic choices.
The Biologics & Injectables Index helps your team understand payer perspectives and decision‑making by capturing unblinded insights from active P&T participants and access controllers across plans, PBMs, providers, and IDNs, revealing how they evaluate biologic and injectable therapies.
The Biologics & Injectables Index identifies trends in coverage, site‑of‑care dynamics, and emerging therapies by tracking quarterly payer reactions, access management topics, and therapeutic‑area shifts that highlight evolving market dynamics.
The Biologics & Injectables Index informs market access and commercial strategy by providing forward‑looking payer, HCP, and practice‑manager insights that clarify anticipated coverage changes, administration burdens, and competitive pressures across Commercial and Medicare lines of business.
Key Insights From MMIT
Access Trends for Innovative Technology Cell and Gene Therapies, Biomarkers, and Telemedicine
This webinar explores evolving access trends for innovative healthcare technologies, including cell and gene therapies, biomarker testing, and telemedicine. Using CAR T-cell therapy as a primary example, the session highlights the growing complexity of payer coverage, prior authorization requirements, reimbursement challenges, and patient support needs for high-cost specialty treatments. Speakers also discuss barriers to biomarker testing adoption, the rapid expansion of telemedicine during COVID-19, and the importance of outcomes evidence, streamlined payer policies, and coordinated manufacturer support to improve patient access across emerging healthcare innovations.
What you’ll learn:
- Learn how evolving payer policies, prior authorization requirements, and outcomes-based contracting are shaping access to innovative cell and gene therapies like CAR T-cell treatments.
- Discover the key barriers impacting biomarker and genetic testing adoption, including payer coverage challenges, clinical utility concerns, and provider administrative burden.
- Understand how COVID-19 accelerated telemedicine adoption and what payers, providers, and manufacturers must do to support long-term virtual care access and patient engagement.
Solutions to Support Your Strategy
Enhance the Biologics & Injectables Index with related solutions that provide broader visibility into coverage decisions, patient journeys, and emerging therapies. This enables your team to move from insight to confident, informed action.